TY - JOUR
T1 - Pegase 03
T2 - A prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer
AU - Biron, P.
AU - Durand, M.
AU - Roché, H.
AU - Delozier, T.
AU - Battista, C.
AU - Fargeot, P.
AU - Spaeth, D.
AU - Bachelot, T.
AU - Poiget, E.
AU - Monnot, F.
AU - Tanguy, M. L.
AU - Curé, H.
PY - 2008/3
Y1 - 2008/3
N2 - Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction therapy. Eligible patients received four induction cycles with FEC 100 (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2). Patients with objective response (N = 179) were randomized to one cycle of HDC (cyclophosphamide 6000 mg/m2 and thiotepa 800 mg/m2 (CHUT)) and stem cell support (N = 88), or no further treatment (N = 91). All patients were observed until disease progression or death. One toxic death occurred after CHUT. Other toxicities were manageable. The response rate at 3 months was higher in the intensification arm: 82.7% (25.3% complete response (CR)) versus 59.2% (14.1% CR) (P = 0.0002). Median follow-up was 48 months. Median DFS was 11 and 6.6 months in the intensification and the observation arms, respectively (P = 0.0001). There was no survival difference: 33.6 versus 27.3% OS at 3 years (P = 0.8) and 22.9 versus 22.3 months median time to relapse in the intensification and observation arms, respectively. In this randomized trial, HDC with CHUT improved DFS but not OS, corroborating findings from earlier trials.
AB - Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction therapy. Eligible patients received four induction cycles with FEC 100 (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2). Patients with objective response (N = 179) were randomized to one cycle of HDC (cyclophosphamide 6000 mg/m2 and thiotepa 800 mg/m2 (CHUT)) and stem cell support (N = 88), or no further treatment (N = 91). All patients were observed until disease progression or death. One toxic death occurred after CHUT. Other toxicities were manageable. The response rate at 3 months was higher in the intensification arm: 82.7% (25.3% complete response (CR)) versus 59.2% (14.1% CR) (P = 0.0002). Median follow-up was 48 months. Median DFS was 11 and 6.6 months in the intensification and the observation arms, respectively (P = 0.0001). There was no survival difference: 33.6 versus 27.3% OS at 3 years (P = 0.8) and 22.9 versus 22.3 months median time to relapse in the intensification and observation arms, respectively. In this randomized trial, HDC with CHUT improved DFS but not OS, corroborating findings from earlier trials.
UR - http://www.scopus.com/inward/record.url?scp=41549148282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41549148282&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1705935
DO - 10.1038/sj.bmt.1705935
M3 - Article
C2 - 18037940
AN - SCOPUS:41549148282
VL - 41
SP - 555
EP - 562
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 6
ER -